Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Advanced or Metastatic Solid Malignancies × Ipilimumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 3 Neoplasm Metastasis 2 Uveal Melanoma 1 Prostatic Neoplasms 1 Lung Neoplasms 1 Gliosarcoma 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Advanced or Metastatic Solid Malignancies 1 Adenocarcinoma of Lung 1

Interventions

sitravatinib 1 pembrolizumab 1 Nivolumab 1 Ipilimumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04887870 2025-10-10

Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

Mirati Therapeutics Inc.

Phase 2/3 Completed

Advanced or Metastatic Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon ⚡